News

The FDA Approves Powerful HIV Prevention Drug
But the Trump administration’s cuts to HIV programs in the U.S. and abroad could undermine the drug’s rollout.
FDA approves long-lasting HIV-prevention drug
The Food and Drug Administration has approved a new drug that could prevent HIV infections with just two shots every year and ...
FDA approves powerful HIV drug that nearly eliminated spread in clinical trials
The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...
FDA approves HIV prevention drug taken as twice-yearly injection
Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...
Children’s cough syrup recalled for bacterium that can cause food poisoning
A children’s cough syrup has been recalled due to the rick of it causing bacterial infection. According to the U.S. Food and ...
FDA Approves a Twice-Yearly Shot to Prevent HIV
The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.
Regulators Approve a Twice-Yearly Shot to Prevent H.I.V. Infection
The drug could change the course of the AIDS epidemic. But the Trump administration has gutted the programs that might have ...
Kraft Heinz, General Mills to remove all artificial dyes from food products
Kraft Heinz and General Mills announced Tuesday that they plan to remove artificial dyes from their food products by the end ...
FDA Offers Speedier Approvals to Drug Companies Aligning With 'National Priorities'
The initiative, referred to as the Commissioner's National Priority Voucher program, allows drug developers to participate in ...
Two major US food producers to remove artificial dyes from products sold domestically
Kraft Heinz will be pulling artificial dyes from its U.S. products starting in 2027 and will no longer roll out new products ...
Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug
Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives ...